• Loading stock data...

Global WholeHealth Partners Corp (OTC:GWHP) Gives an Update on Salud Previa of Tijuana, MX; Salud Previa is Located at Av. Paseo del Rio 6672 N2 L204 3ra Etapa Rio, Tijuana, Baja California, www.SaludPrevia.com


SAN CLEMENTE, CA, July 12, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Global WholeHealth Partners Corp (OTC:GWHP) gives an update on Salud Previa of Tijuana, MX; Salud Previa is located at Av. Paseo del Río 6672 N2 L204 3ra Etapa Río, Tijuana, Baja California.

Salud Previa, www.SaludPrevia.com, has a staff of Sales Agents, Distributors, Medical Doctors and Administrators. Salud Previa has its own transportation people for logistics. With contacts with Pharmacies, Doctors, Hospitals, and the Government of Mexico, Salud Previa is moving fast with a variety of tests in Tijuana, Baja California, Mazatlán, Sinaloa, Monterrey, Nuevo León, Torreón, Coahuila and Mexico City. Salud Previa’s first order was made up of drug tests, pregnancy tests and COVID-19 Antibody and Antigen tests.  Our partnership with Salud Previa is based on Global’s core business of all diagnostic tests, not just COVID-19.

Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest lines of COVID-19 tests. Global’s WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer is capable of detecting all the current identified SARS-CoV-2 viruses.  The strains identified in the United Kingdom (B.1.1.7) , South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein, Global understands the need to be ahead of the virus to conquer the virus. Global’s Antigen test will detect the NEW DELTA variant.

Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.

Global Wholehealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. with an FDA Certificate of Exportability (2260-11-2019).  The company was founded on March 7, 2013, and is headquartered in San Clemente, CA.

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, The Company offers 56 products FDA approved and many are Approved for OTC use, and 15 POC products approved by the CLIA WAVED FDA.

Media Contact:
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: [email protected]
www.gwhpcorp.com

Forward-Looking Statements

This press release contains “forward-looking statements.”  Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Source: Global WholeHealth Partners Corp.

            © 2021 GlobeNewswire, Inc.

AS SEEN OR HEARD ON